KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Free Cash Flow (2023 - 2025)

Biocryst Pharmaceuticals' Free Cash Flow history spans 9 years, with the latest figure at $293.0 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 5076.53% year-over-year to $293.0 million; the TTM value through Dec 2025 reached $346.8 million, up 752.49%, while the annual FY2025 figure was $346.8 million, 752.49% up from the prior year.
  • Free Cash Flow reached $293.0 million in Q4 2025 per BCRX's latest filing, up from $41.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $293.0 million in Q4 2025 to a low of -$53.9 million in Q1 2024.
  • Average Free Cash Flow over 3 years is $16.5 million, with a median of -$6.6 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: dropped 13.1% in 2024, then soared 5076.53% in 2025.
  • A 3-year view of Free Cash Flow shows it stood at -$7.3 million in 2023, then grew by 19.39% to -$5.9 million in 2024, then skyrocketed by 5076.53% to $293.0 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Free Cash Flow are $293.0 million (Q4 2025), $41.0 million (Q3 2025), and $40.4 million (Q2 2025).